Stock listing
Frankfurt:UUDA Syntara Limited Aktie
German listing (Frankfurt) of Syntara Limited · home listing ASX:SNT
Follow Syntara Limited into a list and get an email when it puts out news.
Share price · FWB:UUDA
€0.012 EUR 0.000 (0.0%)
Close on Nov 19, 2026
- Day range
- €0.012 – €0.012 EURNov 19, 2026
- Traded on an average day
- €9 EURMedian day 0 shares · 64 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:SNT · Home | $0.014 AUD | -0.001 (-3.4%) | 2,383,516 | $0.013 | $0.014 | $0.013 | $0.015 | Close on Nov 20, 2026 |
| Frankfurt:UUDA | €0.012 EUR | 0.000 (0.0%) | — | €0.012 | €0.012 | €0.012 | €0.012 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · FWB:UUDA · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.012 | 0.000 | 0.0% | €0.012 | €0.012 | €0.012 | 0 | |
| €0.012 | +0.006 | +100.0% | €0.0060 | €0.012 | €0.0060 | 9,163 | |
| €0.0060 | 0.000 | 0.0% | €0.0060 | €0.0060 | €0.0060 | 0 | |
| €0.0060 | 0.000 | 0.0% | €0.0060 | €0.0060 | €0.0060 | 0 | |
| €0.0060 | 0.000 | 0.0% | €0.0060 | €0.0060 | €0.0060 | 0 | |
| €0.0060 | +0.001 | +20.0% | €0.0060 | €0.0060 | €0.0060 | 0 | |
| €0.0050 | -0.006 | -54.5% | €0.0050 | €0.0050 | €0.0050 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | +0.001 | +10.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.010 | +0.001 | +11.1% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.0090 | 0.000 | 0.0% | €0.0090 | €0.0090 | €0.0090 | 0 | |
| €0.0090 | -0.001 | -10.0% | €0.0090 | €0.0090 | €0.0090 | 0 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.010 | -0.010 | -50.0% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.020 | 0.000 | 0.0% | €0.020 | €0.020 | €0.020 | 0 | |
| €0.020 | 0.000 | 0.0% | €0.020 | €0.020 | €0.020 | 0 | |
| €0.020 | 0.000 | 0.0% | €0.020 | €0.020 | €0.020 | 0 | |
| €0.020 | 0.000 | 0.0% | €0.020 | €0.020 | €0.020 | 0 | |
| €0.020 | 0.000 | 0.0% | €0.020 | €0.020 | €0.020 | 0 | |
| €0.020 | 0.000 | 0.0% | €0.020 | €0.020 | €0.020 | 0 | |
| €0.020 | 0.000 | 0.0% | €0.020 | €0.020 | €0.020 | 0 | |
| €0.020 | +0.009 | +81.8% | €0.020 | €0.020 | €0.020 | 5,000 | |
| €0.011 | +0.002 | +22.2% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.0090 | -0.001 | -10.0% | €0.0090 | €0.0090 | €0.0090 | 0 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.010 | +0.001 | +11.1% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.0090 | -0.001 | -10.0% | €0.0090 | €0.0090 | €0.0090 | 0 | |
| €0.010 | -0.001 | -9.1% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.011 | 0.000 | 0.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.011 | +0.002 | +22.2% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.0090 | -0.001 | -10.0% | €0.0090 | €0.0090 | €0.0090 | 0 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 40,000 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.010 | -0.001 | -9.1% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.011 | +0.001 | +10.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.010 | -0.001 | -9.1% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.011 | +0.001 | +10.0% | €0.011 | €0.011 | €0.011 | 0 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 0 | |
| €0.010 | 0.000 | 0.0% | €0.010 | €0.010 | €0.010 | 0 |
- Ticker
- Frankfurt:UUDA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 18, 2026
Results of Meeting
Latest deck · Nov 19, 2026
Shareholder Meeting (November 2026)
Shareholder meeting · 17 slides
Latest news
Results of Meeting
Nov 18, 2026
Closed €0.012 (0.0%) on Nov 19, 2026
CEO Presentation
Nov 18, 2026
Closed €0.012 (0.0%) on Nov 19, 2026
Chair's Address to Shareholders
Nov 18, 2026
Closed €0.012 (0.0%) on Nov 19, 2026
Syntara Pauses SNT-9465 Phase 1b Recruitment
Nov 9, 2026
Closed €0.011 (0.0%) on Nov 10, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Oct 29, 2026
Closed €0.011 (0.0%) on Oct 30, 2026
Notice of Annual General Meeting/Proxy Form
Oct 19, 2026
Closed €0.011 (0.0%) on Oct 20, 2026
Investor Presentation Canaccord Drug & Device Conference
Oct 12, 2026
Closed €0.011 (0.0%) on Oct 13, 2026
Further significant results from SNT-4728 iRBD Phase 2 trial
Oct 6, 2026
Closed €0.0090 (0.0%) on Oct 7, 2026
Notification regarding unquoted securities - SNT
Oct 4, 2026
Closed €0.01 (0.0%) on Oct 5, 2026
Syntara expands SNT-9465 skin scarring study
Sep 30, 2026
Closed €0.02 (0.0%) on Oct 1, 2026
Syntara Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 29 in the last 12 months · 139 in all · newest Nov 18, 2026 · oldest 2016
- Decks
- 41 decks · latest Nov 19, 2026
Where Syntara Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:SNT · Home listing | ASX | Australia | AUD |
| LS Exchange:A3E4P8 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3E4P8 | Lang & Schwarz | Germany | EUR |
| Frankfurt:UUDA · This page | Frankfurt | Germany | EUR |
| OTC:PMXSF | OTC | United States | USD |
| Dusseldorf:UUDA | Dusseldorf | Germany | EUR |
| Munich:UUDA | Munich | Germany | EUR |
| Stuttgart:UUDA | Stuttgart | Germany | EUR |
Valuation
EV/sales 2.0× against a median of 15.6×: the lowest of 4 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $13.94M AUD
- P/E
- Loss
- EV/sales
- 2.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.7×
- Gross margin
- −6.5%
- Operating margin
- −235.2%
- Net margin
- −129.8%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Syntara Limited · ASX:SNT | US$18.20M | US$9.23M | n/a | 2.0× | n/a | 1.7× | −129.8% | 0.0× | n/a |
| Adicet Bio, Inc. · NASDAQ:ACET | US$20.03M | US$5.02M | n/a | n/a | n/a | 0.2× | n/a | 0.1× | 2.02 |
| IGC Pharma, Inc. · AMEX:IGC | US$19.60M | US$19.19M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.09 |
| Provectus Biopharmaceuticals, Inc. · OTC:PVCT | US$19.12M | US$18.94M | n/a | n/a | n/a | n/a | n/a | n/a | -0.21 |
| LeonaBio, Inc. · NASDAQ:LONA | US$19.03M | −US$12.82M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.04 |
| Cocrystal Pharma, Inc. · NASDAQ:COCP | US$18.30M | US$14.69M | n/a | 33.8× | n/a | 6.8× | n/a | 0.5× | 1.21 |
| Marker Therapeutics, Inc. · NASDAQ:MRKR | US$18.17M | US$9.13M | n/a | 4.9× | n/a | 1.7× | −461.1% | 0.0× | 1.49 |
| Resverlogix Corp. · TSX:RVX | US$18.01M | US$95.55M | n/a | n/a | n/a | n/a | n/a | n/a | 0.26 |
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Initiator Pharma A/S · OMXSTO:INIT | US$16.76M | US$15.67M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Neurotech International Ltd. · ASX:NTI | US$16.63M | US$15.06M | n/a | n/a | n/a | 41.1× | n/a | 0.0× | n/a |
| Median of the others | US$18.24M | US$14.87M | 15.6× | 2.8× | −319.8% | 0.0× | 1.09 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.10 AUD · Analysts' mean
- EPS, year to Jun 2027
- -0.005 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Gary Phillips | Chief Executive Officer |
| Tim Luscombe | Chief Financial Officer & Company Secretary |
| Dieter Hamprecht | Head of Chemistry |
| Jana Baskar | Chief Medical Officer |
| Kristen Morgan | Head of Medical and Regulatory Affairs |
| Wolfgang Jarolimek | Head of Drug Discovery |
Board
| Director | Role |
|---|---|
| Kathleen Metters | Independent Chair |
| Hashan De Silva | Non-Executive Director |
| Simon Green | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | Apr 28, 2026 | −12.5% |
| Quarter to Sep 30, 2025 | Nov 28, 2025 | −5.9% |
| Q4 2025 | Aug 28, 2025 | +1.9% |
| Quarter to Mar 31, 2025 | May 30, 2025 | −5.8% |
| Q2 2025 | Feb 26, 2025 | +3.8% |
| Quarter to Sep 30, 2024 | Nov 29, 2024 | +20.0% |
| Q4 2024 | Aug 30, 2024 | −2.9% |
| Quarter to Mar 31, 2024 | Apr 29, 2024 | −5.9% |
| Q2 2024 | Jan 30, 2024 | +11.8% |
| Quarter to Sep 30, 2023 | Oct 30, 2023 | −3.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Jul 20, 2023 | −3.7% |
| Q2 2023 | Jan 30, 2023 | +1.7% |
| Quarter to Sep 30, 2022 | Oct 30, 2022 | +1.6% |
| Q4 2022 | Aug 30, 2022 | 0.0% |
| Quarter to Mar 31, 2022 | Apr 28, 2022 | −4.0% |
| Q2 2022 | Jan 30, 2022 | +1.0% |
| Quarter to Sep 30, 2021 | Oct 27, 2021 | +8.7% |
| Q4 2021 | Jul 28, 2021 | 0.0% |
| Quarter to Mar 31, 2021 | Jun 4, 2021 | −1.2% |
| Q2 2021 | Jan 28, 2021 | −2.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (November 2026) | Shareholder meeting | 17 slides | Nov 19, 2026 |
| Shareholder Meeting (November 2026) | Shareholder meeting | 17 slides | Nov 19, 2026 |
| Canaccord Drug & Device Conference 2026 | Conference | 20 slides | Oct 13, 2026 |
| Corporate Update (July 2026) | Corporate update | 12 slides | Jul 28, 2026 |
| Investor Presentation (July 2026) | Investor deck | 31 slides | Jul 27, 2026 |
| Technical Presentation (July 2026) | Technical | 11 slides | Jul 6, 2026 |
| Investor Presentation (June 2026) | Investor deck | 20 slides | Jun 1, 2026 |
| Investor Presentation (April 2026) | Investor deck | 46 slides | Apr 29, 2026 |
| NWR Virtual Healthcare Conference (March 2026) | Conference | 29 slides | Mar 25, 2026 |
| Euroz Hartleys 2026 Healthcare Forum | Conference | 15 slides | Feb 5, 2026 |
All 41 decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Share purchase plan of new fully paid ordinary shares Closed: A$840,000 raised · A$0.027 a share Use of proceeds: Cash runway to Q3 2027: clinical trial readouts and licensing, Phase 2b MF study preparation, patent suite, offer costs | Jun 10, 2026 | US$589,447 |
| Private placement of new fully paid ordinary shares Announced: A$8M · A$0.027 a share · Canaccord Genuity (Australia) Limited +1 Dealers: Canaccord Genuity (Australia) Limited (co-lead), Euroz Hartleys Limited (co-lead) Use of proceeds: Five clinical trial readouts in 2026, licensing discussions, Phase 2b myelofibrosis study preparation, patent suite and offer costs; runway to Q3 2027 | Apr 29, 2026 | US$5.71M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.93M | 7.30M | 5.43M | 5.76M | 5.76M | 7.43M | 23.6M | 7.03M | 5.68M | 49.4M |
| Cost of revenue | 7.38M | 223.0K | 8.30M | 2.71M | 9.95M | 15.4M | 16.1M | 15.9M | 1.77M | |
| Gross profit | -450.0K | -223.0K | 3.06M | 3.06M | 7.43M | 7.21M | -9.09M | -10.2M | 47.3M | |
| Research and development | 7.38M | 8.71M | 7.22M | 4.77M | 6.34M | 8.66M | ||||
| Selling, general and administrative | 1.51M | 9.00M | 17.3M | 15.5M | 14.1M | 14.9M | 14.5M | 15.5M | 15.1M | 14.2M |
| Operating income | -16.3M | -22.1M | -14.1M | -18.7M | -19.8M | -19.9M | -4.40M | -20.9M | -24.5M | 16.9M |
| Depreciation and amortization | 146.0K | 223.0K | 232.0K | 232.0K | 1.85M | 3.24M | 3.15M | 3.24M | 2.62M | 3.11M |
| EBITDA | -16.2M | -21.9M | -13.8M | -18.5M | -18.0M | -16.7M | -1.25M | -17.6M | -21.9M | 20.0M |
| Interest expense | 10.0K | 30.0K | 386.0K | 223.0K | 223.0K | 369.0K | 238.0K | 563.0K | 623.0K | |
| Income before tax | -9.61M | -12.3M | -13.7M | -18.2M | -18.7M | -1.94M | -3.12M | -19.1M | -26.0M | 6.26M |
| Income tax | -4.73M | -5.61M | -4.56M | -5.25M | -4.90M | -148.0K | -5.16M | -8.00K | -169.0K | |
| Net income | -8.99M | -7.92M | -15.1M | -11.4M | -1.94M | -2.97M | -13.9M | -20.1M | 6.43M | -18.3M |
| Earnings per share, basic | -0.01 | -0.01 | -0.01 | -0.02 | -0.00 | -0.01 | -0.04 | -0.05 | 0.02 | -0.06 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 13.6M | 15.1M | 3.52M | 9.23M | 8.94M | 18.7M | 14.8M | 31.1M | 31.1M | 21.5M |
| Short-term investments | 2.77M | 6.00M | ||||||||
| Receivables | 19.0K | 5.66M | 7.48M | 7.64M | 2.74M | 6.94M | 7.19M | 2.39M | 4.43M | |
| Inventory | 1.64M | 2.34M | 3.64M | 2.63M | 2.12M | 2.40M | 2.57M | |||
| Current assets | 18.8M | 21.0M | 9.77M | 18.7M | 19.2M | 25.3M | 24.5M | 40.6M | 36.0M | 28.6M |
| Property, plant and equipment | 180.0K | 383.0K | 1.84M | 3.21M | ||||||
| Total assets | 19.1M | 21.4M | 10.4M | 24.0M | 25.2M | 33.6M | 35.4M | 52.7M | 50.1M | 45.4M |
| Accounts payable | 1.23M | 2.52M | 614.0K | 1.58M | 615.0K | 1.24M | 1.76M | 2.20M | 2.13M | 3.32M |
| Current liabilities | 2.86M | 5.34M | 5.45M | 8.03M | 6.10M | 7.89M | 6.83M | 8.11M | 8.24M | 10.5M |
| Total debt | 84.0K | 2.04M | 4.29M | 6.32M | 8.15M | 7.17M | 8.27M | 9.25M | ||
| Total liabilities | 2.92M | 5.42M | 5.70M | 14.5M | 14.4M | 30.7M | 34.0M | 37.9M | 39.0M | 41.9M |
| Shareholders' equity | 16.2M | 16.0M | 4.68M | 9.56M | 10.8M | 2.85M | 1.43M | 14.8M | 11.1M | 3.52M |
| Shares outstanding | 1.67B | 1.47B | 1.19B | 655.6M | 562.9M | 407.3M | 394.7M | 381.4M | 319.7M | 318.5M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9.78M | -11.1M | -7.28M | -16.3M | 3.07M | -13.3M | -19.8M | 12.2M | -15.3M | |
| Capital spending | -2.00K | 0 | -7.00K | -138.0K | -307.0K | -647.0K | -574.0K | -981.0K | -840.0K | -723.0K |
| Free cash flow | -9.78M | -11.1M | -14.5M | -7.42M | -16.6M | 2.42M | -13.9M | -20.8M | 11.4M | -16.0M |
| Cash from investing | -2.00K | 4.18M | -131.0K | -306.0K | -644.0K | -574.0K | -981.0K | -884.0K | -723.0K | |
| Cash from financing | 8.26M | 18.5M | 7.20M | 6.98M | 6.63M | 1.52M | -2.50M | 20.8M | -1.75M | -1.72M |
| Dividends paid | -2.25M | -2.38M | -2.31M | |||||||
| Share buybacks | -494.0K | -1.35M | -678.0K | -678.0K | -741.0K | -301.0K | 0 | |||
| Change in cash | -1.51M | 11.6M | -5.80M | 293.0K | -9.78M | 3.95M | -16.4M | 51.0K | 9.57M | -17.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Results of Meeting | Nov 18, 2026 | Meeting outcome | ASX |
| CEO Presentation | Nov 18, 2026 | Other filings | ASX |
| Chair's Address to Shareholders | Nov 18, 2026 | Other filings | ASX |
| Syntara Pauses SNT-9465 Phase 1b Recruitment | Nov 9, 2026 | Operations update | ASX |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
| Notice of Annual General Meeting/Proxy Form | Oct 19, 2026 | Meeting notice | ASX |
| Investor Presentation Canaccord Drug & Device Conference | Oct 12, 2026 | Other filings | ASX |
| Further significant results from SNT-4728 iRBD Phase 2 trial | Oct 6, 2026 | Other filings | ASX |
| Notification regarding unquoted securities - SNT | Oct 4, 2026 | Other filings | ASX |
All 139 filings
Cap table
Built by 6ix from Syntara Limited’s releases · as of Jun 10, 2026
- Common shares
- 1,964,519,275
- Fully diluted
- 1,964,519,275
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,964,519,275 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,964,519,275 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Dieter Hamprecht | Head of Chemistry · Since at least Nov 5, 2026 |
| Gary Phillips | Chief Executive Officer · Since at least Jul 28, 2026 |
| Hashan De Silva | Non-Executive Director · Since at least Nov 5, 2026 |
| Jana Baskar | Chief Medical Officer · Since at least Nov 5, 2026 |
| Kathleen Metters | Independent Chair · Since at least Nov 5, 2026 |
| Kristen Morgan | Head of Medical and Regulatory Affairs · Since at least Nov 5, 2026 |
| Simon Green | Non-Executive Director · Since at least Nov 5, 2026 |
| Tim Luscombe | Chief Financial Officer & Company Secretary · Since at least Nov 4, 2026 |
| Wolfgang Jarolimek | Head of Drug Discovery · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Syntara Limited.